Brevan Howard Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Brevan Howard Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.52M	Buy	215,845 +107,942	+100%	+$2.43M	0.04%	269
2025 Q4	$2.42M	Buy	107,903 +40,868	+61%	+$1.34M	0.03%	428
2025 Q3	$2.02M	Buy	67,035 +58,874	+721%	+$1.77M	0.01%	558
2025 Q2	$297K	Buy	+8,161	New	+$294K	﹤0.01%	1556
2025 Q1	–	Sell	-35,201	Closed	-$1.48M	–	1401
2024 Q4	$1.48M	Buy	35,201 +18,960	+117%	+$941K	0.01%	343
2024 Q3	$902K	Buy	+16,241	New	+$827K	0.01%	485
2024 Q2	–	Sell	-9,077	Closed	-$424K	–	1344
2024 Q1	$424K	Buy	+9,077	New	+$428K	﹤0.01%	511

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Brevan Howard Capital Management's RARE Position: Q1 2026 in Review

Brevan Howard Capital Management increased its Ultragenyx Pharmaceutical (RARE) stake by 100% in Q1 2026, buying an estimated $2.43M and bringing the position to 215,845 shares worth $4.52M. The position accounts for 0.04% of the portfolio, ranked #269.

Brevan Howard Capital Management first reported a position in RARE in Q1 2024 and has held it in 7 quarters since. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Brevan Howard Capital Management held 215,845 shares of Ultragenyx Pharmaceutical worth $4.52M as of Q1 2026.
Brevan Howard Capital Management bought 107,942 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $2.43M.
Ultragenyx Pharmaceutical made up 0.04% of Brevan Howard Capital Management's portfolio in Q1 2026, its #269 holding.
Brevan Howard Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and has held it in 7 quarters since.
295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.